anbenitamab + docetaxel (albumin-bound)

anbenitamab + HB1801 is an investigational combination regimen consisting of anbenitamab (KN026), a HER2-targeted bispecific antibody, and HB1801, an albumin-bound nanoparticle formulation of docetaxel. Anbenitamab simultaneously binds to two non-overlapping extracellular domains of HER2 (domains II and IV), which are the binding sites of pertuzumab and trastuzumab, respectively. This dual binding promotes receptor clustering, endocytosis, and lysosomal degradation, thereby inhibiting downstream HER2 signaling. HB1801 is a solvent-free formulation of docetaxel encapsulated in human serum albumin nanoparticles, which avoids the use of polysorbate 80 and ethanol, eliminating the need for steroid premedication and allowing rapid administration at higher concentrations. The combination is being co-developed by Alphamab Oncology and CSPC for the treatment of HER2-positive breast cancer, showing significant efficacy in phase 3 trials (such as Neo-Healer and HEALER) in both neoadjuvant and first-line metastatic settings.

Other names

Ennituo + HB1801Ennituo plus HB1801KN026 + HB1801KN026 plus HB1801KN-026 plus HB1801KN 026 plus HB1801SYS6092 + HB1801SYS6092 plus HB1801SYS-6092 plus HB1801SYS 6092 plus HB1801anbenitamab + HB1801anbenitamab + albumin-bound docetaxelanbenitamab + docetaxel (albumin-bound)anbenitamab plus HB1801anbenitamab plus albumin-bound docetaxelanbenitamab plus docetaxel (albumin-bound)anituo monoclonal antibody + HB1801anituo monoclonal antibody plus HB1801